Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026Business Wire · 1 hr ago
Agenus to Provide Third Quarter 2026 Financial Report and Development UpdateBusiness Wire · 2 days ago
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer TrialMarketBeat · 4 days ago
Agenus Inc. (NASDAQ:AGEN) Stock Has Consensus Price Target of $24.50 According to AnalystsDefense World · Oct 16, 2026
Agenus to Participate in Chardan's 10th Annual Healthcare Investor ConferenceBusiness Wire · Oct 9, 2026
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerBusiness Wire · Oct 8, 2026Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.05 | -$0.01 | Miss |
| May 11, 2026 | $2.10 | $1.02 | Miss |
| Mar 16, 2026 | -$1.27 | $0.56 | Beat |
| Nov 10, 2025 | $2.63 | $1.94 | Miss |
| Aug 11, 2025 | -$0.78 | -$1.00 | Miss |
| May 12, 2025 | -$1.61 | -$1.03 | Beat |